Clinical trials: Palmoplantar Psoriasis
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Psoriasis, Psoriatic Arthritis
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01690299
- Testing
- Apremilast, Etanercept
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Palmoplantar Pustulosis (PPP)
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of…
- Trial name
- NCT07503652
- Testing
- Xeligekimab Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Hospital of China Medical University
Psoriasis Palm & Soles
Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current
Interferential current has shown promising results for treating psoriasis with a good tolerance. Prospective randomized studies versus placebo are required to confirm the interest of such an approach.
- Trial name
- NCT01765985
- Testing
- PSORIAMED
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Pr PASSERON
Palmoplantar Pustulosis
Immune Signature of Palmoplantar Pustulosis
This study is being done to learn more about a less common "type" of psoriasis, called palmoplantar pustulosis (PPP). The majority of the current treatments used for this type of psoriasis have only a moderate effect on PPP.
- Trial name
- PPP (NCT01780857)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Palmoplantar Pustulosis
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.
- Trial name
- ProPuP (NCT04459507)
- Testing
- No intervention
- Where
- 39 sites in Japan
- Volunteers
- 276 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT03988335
- Testing
- RIST4721
- Where
- 17 sites in Canada, Germany
- Volunteers
- 35 people
- Sponsor
- Aristea Therapeutics, Inc.
Palmoplantaris Pustulosis
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP.
- Trial name
- NCT04057937
- Testing
- Apremilast
- Where
- 22 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Amgen
Palmoplantar Pustulosis
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
- Trial name
- NCT05710185
- Testing
- Deucravacitinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Brigham and Women's Hospital
Palmoplantar Pustulosis (PPP)
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles.
- Trial name
- NCT04451720
- Testing
- Risankizumab
- Where
- 39 sites in Japan
- Volunteers
- 119 people
- Sponsor
- AbbVie
Palmoplantar Pustulosis
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT04061252
- Testing
- KHK4827
- Where
- 2 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Palmoplantar Pustulosis
Picankibart in Palmoplantar Pustulosis
1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to…
- Trial name
- NCT07552454
- Testing
- Picankibart
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while…
- Trial name
- PASI (NCT07545902)
- Testing
- PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- ICIM International S.r.l.
Palmoplantar Pustulosis (PPP)
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally.
- Trial name
- NCT07530367
- Testing
- Tofacitinib, Imatinib
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Psoriasis, Contact Dermatitis of Hand
An Open-label Controlled Trial: Effectiveness of Balneotherapy in Palmoplantar Psoriasis and Contact Dermatitis.
Patients who had an indication for phototherapy were included in this study. The treatment was used as a monotherapy protocol. The standard protocol for bathing PUVA involved applying 0.01% bath psoralen for 15 minutes, while the…
- Trial name
- NCT06458868
- Testing
- salt water or tap water before UVA
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Ankara University
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris
The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases
This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas and other…
- Conditions
- Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
- Trial name
- NCT00005660
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Palmoplantar Pustulosis
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.
- Trial name
- NCT05194839
- Testing
- RIST4721
- Where
- 51 sites in United States, Canada and 5 more
- Volunteers
- 79 people
- Sponsor
- Aristea Therapeutics, Inc.
Psoriasis
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
- Trial name
- IMMprint (NCT04713592)
- Testing
- Risankizumab
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 174 people
- Sponsor
- AbbVie
Palmoplantar Pustular Psoriasis
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a…
- Trial name
- NCT02008890
- Testing
- Secukinumab 300mg, Secukinumab 150mg
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Palmoplantar Psoriasis
Brodalumab in Palmoplantar Psoriasis
This is a Phase 4 single center, single-arm, open-label study that will evaluate the efficacy and safety of brodalumab in psoriasis patients as well as the impact on quality of life in addition to clinical photography.
- Trial name
- NCT04622033
- Testing
- Brodalumab
- Volunteers
- 10 people
- Sponsor
- First OC Dermatology